NTHI Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.890

Open

4.890

VWAP

4.71

Vol

28.33K

Mkt Cap

120.70M

Low

4.610

Amount

133.55K

EV/EBITDA(TTM)

--

Total Shares

26.01M

EV

130.50M

EV/OCF(TTM)

--

P/S(TTM)

2.32K

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).

Show More

Events Timeline

(ET)

2026-04-10

17:20:00

NeOnc Technologies Files to Sell 680,558 Shares of Common Stock

2026-04-10

16:50:00

Company Signs $75M Equity Distribution Agreement with BTIG

2026-04-02 (ET)

2026-04-02

13:10:00

NeOnc Technologies Files $300M Mixed Securities Shelf

2026-03-13 (ET)

2026-03-13

09:10:00

NeOnc Appoints David Choi as Chief Accounting Officer

2026-03-04 (ET)

2026-03-04

08:10:00

NeOnc Announces NEO212 Clinical Trial Data and Hosts Conference Call

2026-02-06 (ET)

2026-02-06

17:00:00

NeOnc Technologies Files to Sell 2.95M Shares of Common Stock

2026-01-30 (ET)

2026-01-30

09:20:00

NeOnc Technologies Signs Securities Purchase Agreement, Expected to Raise Approximately $16 Million

News

Newsfilter

05-29Newsfilter

AI Revolutionizing Drug Delivery in Biotech Sector

Globenewswire

05-28Globenewswire

Biotech Sector Approaches Critical Inflection Points

Newsfilter

05-06Newsfilter

Insider Buying Signals Strong Confidence Across Key Companies

Newsfilter

02-27Newsfilter

NeOnc Technologies to Host Investor Conference Call on March 4, 2026

Yahoo Finance

02-07Yahoo Finance

New Show Airing on Bloomberg Television

Newsfilter

01-30Newsfilter

NeOnc Secures $16 Million PIPE Investment for CNS Cancer Therapies

Valuation Metrics

The current forward P/E ratio for NeOnc Technologies Holdings Inc (NTHI.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess NeOnc Technologies Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stocks have have hit pivot bottom

Intellectia · 247 candidates

Rsi Category: moderate, oversoldMoving Average Relationship: PriceAboveMA5Month Price Change Pct: $-45.00 - $-1.00Support Resistance Relationship: PriceAroundSupportMonthly Average Dollar Volume: >= 150,000

Ticker

Name

Market Cap$

Lifecore Biomedical Inc

149.91M

NovaGold Resources Inc

3.54B

GoldMining Inc

243.68M

Clearpoint Neuro Inc

282.10M

Paramount Gold Nevada Corp

137.45M

Can Fite Biopharma Ltd

6.59M

Whales Holding NTHI

HighPoint Advisor Group, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is NeOnc Technologies Holdings Inc (NTHI) stock price today?

The current price of NTHI is 4.64 USD — it has decreased -3.13

What is NeOnc Technologies Holdings Inc (NTHI)'s business?

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).

What is the price predicton of NTHI Stock?

Wall Street analysts forecast NTHI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTHI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is NeOnc Technologies Holdings Inc (NTHI)'s revenue for the last quarter?

NeOnc Technologies Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is NeOnc Technologies Holdings Inc (NTHI)'s earnings per share (EPS) for the last quarter?

NeOnc Technologies Holdings Inc. EPS for the last quarter amounts to -0.73 USD, increased 508.33

How many employees does NeOnc Technologies Holdings Inc (NTHI). have?

NeOnc Technologies Holdings Inc (NTHI) has 5 emplpoyees as of May 31 2026.

What is NeOnc Technologies Holdings Inc (NTHI) market cap?

Today NTHI has the market capitalization of 120.70M USD.